Windtree Therapeutics, Inc. (WINT) Stock Surged 40.01% Pre-Market, Here’s Why

Windtree Therapeutics, Inc. (WINT) stock soared 40.01% in the pre-market trading session at the price of $1.40 after reporting topline data from its SEISMiC study.

Windtree is advancing numerous next-gen interventions to treat acute pulmonary and cardiovascular diseases. Using the latest clinical, technological, and scientific techniques, WINT is formulating multi-asset compounds with a capacity to activate SERCA2a. The company’s lead product candidate, istaroxime, is the first-in-class therapy for heart failure and early-stage cardiogenic shock.

SEISMiC Phase-II Study Data

On 20th April 2022, WINT published positive results of istaroxime in rapidly increasing systolic blood pressure, which is the critical clinical goal in treating patients with cardiogenic shock. The Phase-II SEISMiC study is an international, double-blind, randomized, placebo-controlled clinical study registering 60 patients with SCAI stage B cardiogenic shock caused by heart failure.

The Phase-II clinical study evaluated two istaroxime doses, 1.5 µg/kg/min in the first group and 1. µg/kg/min in the second group. Over six hours following the infusion, the primary endpoint showed a distinction in the SBP area under the curve. Secondary endpoints had characterized shifts in blood pressure after 24 hours.

WINT Market Outlook

The stock is excited to proceed with the development of istaroxime and expects to publish a complete presentation of the clinical data in the upcoming weeks. The commercialization of cardiogenic shock is an essential component of the AHF program. Looking onwards, WINT expects to proceed toward the other stages in the cardiogenic shock program. The company has scheduled a meeting with regulatory agencies to clear the path of product approval.


The year 2021 marks a fruitful period for Windtree as the stock advanced towards numerous significant milestones. Meanwhile, the company has initiated activities for the Phase-III AHF clinical trial that will base on positive Phase-II data. WINT also continued study preparations for further development of istaroxime, including a proposed extension to the cardiogenic shock clinical study.

Leave a Comment

Your email address will not be published.